BioLab Fluid GF™ is an amniotic liquid allograft derived from the amniotic fluid within the amniotic sac used to protect, lubricate and cushion.

BioLab Sciences Membrane Wrap™ is a unique DUAL- LAYERED dehydrated human amnion membrane (dHAM) allograft composed primarily of a connective tissue matrix. It is minimally manipulated, preserving the properties that it exhibits in its natural state¹,². The presence of the connective tissue matrix aids in supporting and protecting the wound.
Our products are safe and the quality is carefully controlled. Our products follow stringent FDA regulations and requirements and are classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS.
Amniotic liquid and tissue is abundant in growth factors and cytokines. Growth factors (GFs) are molecules capable of stimulating a variety of cellular processes.
BioLab Sciences amnio products use donated tissue from consenting mothers during scheduled Cesarian births. The tissue is screened and carefully controlled using FDA guidelines.

Partnering for PATIENT and PRACTICE Success

We specialize in integrating amniotic solutions into your practice by working with your team to provide product and billing support, as well as the tools to educate and inform your patients.
As you prepare to offer this solution to your patients, we work with your team to provide training and documentation on the product, the procedure, and patient communication.
We provide training and support for your billing team to submit reimbursement for Medicare and other insurance providers. We provide Insurance Verification services as well as a reimbursement guarantee.
We provide educational materials and tools to support your patient education efforts, always ensuring your patients have the knowledge they need to make an informed decision.


The medial literature has demonstrated over the last 100 years that using placental allografts promotes healing of many conditions.

Amniotic Fluid May be a Safe and Effective Alternative to Hyaluronic Acid for Osteoarthritis Pain: Interim Results

An Amniotic fluid based injection in this study offered pain and functional improvement that was greater at 13 weeks than at 30 days and appears to offer long-lasting relief at higher levels.

Results observed in the first 170 amniotic fluid-treated patients showed their VAS and WOMAC scores improved an average of 68.1% (44mm) and 70.9% (812mm) respectively, at 30 days. Improvements increased at 90 days to 82% for WOMAC and 74% for VAS.

Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers

This meta‐analysis of randomised controlled trials showed that human amniotic membrane plus SOC is effective and safe in treating patients with chronic DFUs, which can significantly increase wound healing rate and reduce complete healing time.

Clinical Study: Amniotic Fluid for Osteoarthritis

This study found that the results of treatment with Amniotic Allograft were superior to Hyaluronic Acid and placebo in this setting. We found significant differences between AA and HA at 3 months, including EQ-5D-5L pain and anxiety subsets; KOOS pain, symptoms, and ADL subsets; and VAS scores for overall pain, pain during strenuous work, and pain during normal daily living.

Amnion Membrane in Diabetic Foot Wounds: A Meta-analysis

The current meta-analysis indicates that the treatment of diabetic foot ulcers with amniotic membrane improves healing rates in diabetic foot ulcers.